- Poster presentation
- Open Access
Vasoactive intestinal peptide inhibits the production of Salmonella-induced inflammatory cytokines by human monocytes
© Askar et al.; licensee BioMed Central Ltd. 2014
Published: 3 December 2014
Systemic salmonella infection is a frequent cause of Gram-negative sepsis. Bacterial lipopolysaccharide in blood triggers immune response by monocytes, which results in overwhelming production of proinflammatory cytokines and pathology in peripheral organs such as the liver, heart and lungs. The mortality rate due to sepsis remains high even after chemotherapeutic clearance of pathogens, due to sustained production of inflammatory mediators. Therefore, anti-inflammatory therapy as an adjunct to antibiotics could reduce the mortality from sepsis.
To date, several studies have evaluated the role of vasoactive intestinal peptide (VIP) as a therapeutic agent in sepsis both in vivo and in vitro since it possesses several desirable biological properties. The peptide, acting via VIP cell receptors, mediates effects by altering production and secretion of inflammatory mediators such as cytokines. VIP has been shown to decrease production of proinflammatory cytokines, ameliorate histopathological changes and inhibit mortality in mice rendered septic by LPS administration. Nothing is known about the effect of VIP on production of proinflammatory cytokines in human monocytes infected by virulent Salmonella.
The aim of the current study, therefore, was to investigate the effect of vasoactive intestinal peptide on the production of inflammatory cytokines in human monocytes exposed to S. Typhimurium 4/74.
Our finding demonstrates that freshly isolated human monocytes produce proinflammatory cytokines such as TNFα, IL-6, IL-1β and also anti-inflammatory cytokines such as IL-4 and IL-10 following bacterial challenge.
However, co-culture of infected monocytes with VIP (10-7 M) significantly reduced (P < 0.05) production of TNFα, IL-6, IL-1β but significantly increased (P < 0.05) concomitant production of anti-inflammatory IL-10.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.